Apr. 27 - Carol L. Williams, PhD, was awarded Eminent Scholar designation at the March meeting of the Board of Trustees of the Medical College of Wisconsin (MCW). She joins Mingyu Liang, MB, PhD, who was named an Eminent Scholar in September 2015, and William Drobyski, MD, and Brian Link, PhD, who were named Eminent Scholars in March 2015.
Apr. 6 - The Medical College of Wisconsin (MCW) has received two grants totaling $2.8 million to investigate treatments for diseases of the kidney. The first grant is a 5-year, $2.3 million grant from the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases to investigate the development of a drug to treat Type 2 diabetes and metabolic syndrome.
Mar. 21 - The Medical College of Wisconsin (MCW) has received a four-year $1.5 million grant from the National Institute of Health’s (NIH) National Institute of Heart, Lung and Blood to continue funding a study focused on how health of the cells lining the inner wall of blood vessels impact the vessels’ reaction to an increase in blood flow.
Feb. 23 - Coryce Haavik, PhD, former pharmacology and toxicology faculty member who held important leadership positions in MCW’s research and graduate education missions, died Feb. 18 while teaching overseas. She was 82 years old.
Using technology and tools that the Medical College of Wisconsin was a world leader in developing, a PhD student in the Graduate School of Biomedical Sciences and her faculty mentor are pursuing brain research with potential to benefit cancer patients.
Dec. 4 - Cecilia J. Hillard, PhD, professor of pharmacology and toxicology and director of the Neuroscience Research Center, has been named associate dean for research at the Medical College of Wisconsin (MCW).Lake Country Now
July 16 - Kathryn M. “Kathy” Gauthier, PhD, associate professor of pharmacology and toxicology, died Monday, July 13. She was 60 years old.
July 14 - John Imig, PhD provides expert comment on the identification of a key mechanism in neuropathic pain by scientists at the University of California, Davis. The discovery could eventually benefit millions of patients with chronic pain from trauma, diabetes, shingles, multiple sclerosis or other conditions that cause nerve damage. UC-Davis
July 13 - John Imig, PhD, (Pharmacology & Toxicology) tells International Business Times that he expects the debut of the PCSK-9 inhibitors (which targets a mutation in the PCSK-9 gene, which causes high cholesterol) will spur companies to invest in this area as scientists continue their search for genetic factors underlying major diseases. International Business Times
External Communications Consultant
(414) 955-4744 (Office)
Richard N. Katschke
Associate Vice President
Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53226
Directions & Maps